Cibc World Market Inc. Has $3.43 Million Position in GE HealthCare Technologies Inc. $GEHC

Cibc World Market Inc. lessened its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 31.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 41,824 shares of the company’s stock after selling 19,619 shares during the period. Cibc World Market Inc.’s holdings in GE HealthCare Technologies were worth $3,430,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of GEHC. Laurel Wealth Advisors LLC acquired a new position in shares of GE HealthCare Technologies during the 4th quarter valued at $26,000. Optima Capital LLC bought a new stake in GE HealthCare Technologies during the 4th quarter valued at $27,000. Godfrey Financial Associates Inc. bought a new stake in GE HealthCare Technologies during the 4th quarter valued at $27,000. Montag A & Associates Inc. increased its stake in GE HealthCare Technologies by 105.4% during the 4th quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock valued at $28,000 after purchasing an additional 175 shares in the last quarter. Finally, Maseco LLP bought a new stake in GE HealthCare Technologies during the 4th quarter valued at $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

GE HealthCare Technologies Price Performance

NASDAQ GEHC opened at $64.67 on Tuesday. The company has a market cap of $29.42 billion, a PE ratio of 15.47, a price-to-earnings-growth ratio of 1.46 and a beta of 0.74. GE HealthCare Technologies Inc. has a 52 week low of $58.75 and a 52 week high of $89.77. The company has a quick ratio of 0.95, a current ratio of 1.22 and a debt-to-equity ratio of 0.95. The firm’s 50-day simple moving average is $66.75 and its two-hundred day simple moving average is $75.48.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.08). The business had revenue of $5.13 billion for the quarter, compared to analysts’ expectations of $5.04 billion. GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. GE HealthCare Technologies’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period last year, the company earned $1.01 earnings per share. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. Research analysts predict that GE HealthCare Technologies Inc. will post 4.89 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on GEHC. Argus reduced their target price on shares of GE HealthCare Technologies from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Oppenheimer restated an “outperform” rating and set a $85.00 price target on shares of GE HealthCare Technologies in a research report on Thursday, April 30th. UBS Group upgraded shares of GE HealthCare Technologies from a “sell” rating to a “neutral” rating and reduced their price target for the company from $75.00 to $69.00 in a research report on Thursday, May 21st. Wells Fargo & Company reduced their price target on shares of GE HealthCare Technologies from $97.00 to $75.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Finally, Rothschild & Co Redburn reduced their price target on shares of GE HealthCare Technologies from $110.00 to $98.00 in a research report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $80.21.

Insider Transactions at GE HealthCare Technologies

In other news, CFO James Saccaro purchased 3,310 shares of the stock in a transaction dated Friday, May 1st. The shares were purchased at an average cost of $60.60 per share, with a total value of $200,586.00. Following the completion of the acquisition, the chief financial officer owned 87,471 shares in the company, valued at $5,300,742.60. This represents a 3.93% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Kevin Lobo purchased 10,000 shares of the stock in a transaction dated Friday, May 22nd. The stock was purchased at an average cost of $64.18 per share, for a total transaction of $641,800.00. Following the completion of the acquisition, the director owned 14,363 shares of the company’s stock, valued at approximately $921,817.34. This represents a 229.20% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 21,847 shares of company stock valued at $1,361,355. Company insiders own 0.36% of the company’s stock.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.